Urban Tapes

The Shkreli Pill

Business EN ↓ 257 episodes

The only pill worth swallowing. Markets, memes, medicine, and mayhem — served straight, no chaser. Watch the video versions on YouTube : https://www.youtube.com/@TheShkreliPill/videos.

Be sure to visit the podcast's website and support the creator: podcasters.spotify.com

Author

Urban Tapes

Category

Business

Podcast website

podcasters.spotify.com

Latest episode

Nov 11, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android almost 10M downloads · 4.7+ rating iOS soon

Episodes

Episode 842: Quantum Run Got Me. SPRB & CAPR is All I Have | Bitcoin Supply | JNJ, ATYR Stock 16.10.2025

In this episode, Martin reflects on the impact of the Quantum run on his portfolio and discusses how SPRB and CAPR have become his main remaining positions. He also shares insights on Bitcoin’s supply dynamics and offers his latest thoughts on JNJ and Atyr stocks.

Episode 841: It Was Over for Lil Man Before It Even Started | Martin Shkreli Funny Livestream Moments 15.10.2025

In this highlight compilation, Martin showcases some of the funniest and most unexpected moments from his livestreams. Featuring quick wit, audience interactions, and the trademark banter that defines his streams, this episode captures the lighter side of Martin’s commentary and community exchanges.

Episode 840: Motley Fool Guy Gets Emotional over Martin Taking him to School 12.10.2025

In this episode, Martin debates a guest known as the “Motley Fool Guy,” whose reactions grow increasingly emotional as Martin challenges his arguments and investment logic. The exchange highlights contrasting perspectives on market optimism, valuation methods, and what it means to be a disciplined investor.

Episode 839: " I Short Fraud and Hype ". The Capital Cycle Guy Gets Mad & Fights Back 12.10.2025

In this episode, Martin doubles down on his philosophy of shorting what he calls “fraud and hype” in the markets. The Capital Cycle Guy pushes back hard, leading to a heated debate over conviction, evidence, and the boundaries between skepticism and bias in trading.

Episode 838: Capital Cycle Guy Confronts Martin on His Short Thesis. Things Get Heated 12.10.2025

In this episode, Martin is confronted by the “Capital Cycle Guy,” who challenges his short thesis in a tense and candid exchange. The discussion dives into differing views on market timing, capital allocation, and risk, offering a rare look at how contrasting investment frameworks collide in real time.

Episode 837: Applovin Stock is Getting to Me. How to Test Your Technical Analysis Theory 11.10.2025

In this episode, Martin discusses his evolving thoughts on Applovin stock and the emotional challenges that can come with holding or trading it. He also outlines practical methods for testing and validating a technical analysis theory, focusing on how to separate intuition from data-backed strategy.

Episode 836: AMD Stock Deep Analysis & Conclusion. What Their OpenAI Chip Deal Actually Is ? 11.10.2025

In this episode, Martin presents an in-depth analysis of AMD stock, breaking down the company’s fundamentals, valuation, and market position. He also examines the details behind AMD’s chip deal with OpenAI, clarifying what the agreement actually entails and how it might influence the company’s outlook.

Episode 835: Spruce Stock Has More Upside, How Rare Disease Drugs Stay Profitable, CAPR Short 10.10.2025

In this episode, Martin explains why he believes Spruce stock still has room for further gains and discusses what makes rare disease drugs maintain profitability over time. He also outlines his short thesis on CAPR and the factors influencing that position.

Episode 834: My Next Short Trade: BTQ Stock. Enzyme Replacement Therapy Origins Explained 10.10.2025

In this episode, Martin outlines his next short trade, focusing on BTQ stock and the reasoning behind his position. He also takes a step back to explain the origins and mechanisms of enzyme replacement therapy, connecting scientific insight with market analysis.

Episode 833: Why My Prediction AI Suddenly Went Long CAT Stock? QURE Stock, Books to Read 09.10.2025

In this episode, Martin explains why his prediction AI unexpectedly shifted to a long position on CAT stock and what factors may have driven the change. He also discusses his current view on QURE stock and shares additional book recommendations for investors interested in data-driven trading.

Episode 832: I'm Down Again. How I Knew Spruce Stock Would 7x, Books to Read, Career Advice 09.10.2025

In this episode, Martin reflects on recent market losses and explains how he identified the setup that led to Spruce stock’s sevenfold increase. He also shares book recommendations that have influenced his thinking and offers career advice for aspiring investors and traders.

Episode 831: A MIRACLE! BREAKTHROUGH Drug Forecast & Analysis. Spruce Biosciences Stock 08.10.2025

In this episode, Martin highlights what he describes as a breakthrough drug development and offers his forecast and analysis of its potential impact. He also takes a closer look at Spruce Biosciences stock, examining the factors that could shape its performance going forward.

Episode 830: OpenAI & AMD Deal is Too Suspicious. Ambarella & Monopar therapeutics Analysis 08.10.2025

In this episode, Martin examines a deal between OpenAI and AMD that he views as unusually suspicious, exploring its possible implications for the market. He also provides detailed analysis of Ambarella and Monopar Therapeutics, outlining the key factors shaping his outlook on both stocks.

Episode 829: You Thought This Was Over, Huh? Let's Get You Ready | BEST OF COMPILATION 06.10.2025

In this episode, Martin presents a special “Best Of” compilation, revisiting key moments, insights, and lessons from previous streams. He highlights major themes and takeaways to help viewers prepare for what’s ahead in the market.

Episode 828: Shorting GPU Providers is The Next Big Move. Prizes for Best Godel Trader! 05.10.2025

In this episode, Martin discusses why he believes shorting GPU providers could be the next major opportunity in the market and explores the factors driving that view. He also announces a competition with prizes for the best-performing Godel traders.

Episode 827: EA Historical Takeover Explained. Rigetti Positive News Didn't Move the Stock 02.10.2025

In this episode, Martin walks through the history of EA’s notable takeover and the broader lessons it offers for investors. He also looks at recent positive news from Rigetti and analyzes why it failed to significantly move the stock.

Episode 826: Still the Easiest Short And I’m Not Talking IonQ. "Big" IBM News, Soundhound Stock 01.10.2025

In this episode, Martin shares what he considers the easiest short opportunity in the market right now — and clarifies that he’s not referring to IonQ. He also discusses notable news from IBM and examines his view on Soundhound stock.

Episode 825: HIMS Turning Into a Binary Bet; My Prediction. Tylenol Autism Drama, OPEN stock drops 25.09.2025

In this episode, Martin shares his view that HIMS is evolving into a binary investment and outlines his prediction for the stock’s future. He also discusses the controversy surrounding Tylenol and autism, and examines the recent drop in Opendoor’s stock.

Episode 824: Burned by the Joby Short. NVDA & OpenAI Deal, BlackRock's Investor Bullish on Quantum 24.09.2025

In this episode, Martin reviews the outcome of his short position in Joby and the lessons taken from the trade. He also discusses the implications of a deal between NVIDIA and OpenAI, and highlights why a BlackRock investor has taken a bullish stance on Quantum.

Episode 823: My Opendoor Position Ruined, Quantum Back in Full Swing. How I'm Using Options 23.09.2025

In this episode, Martin talks about how his Opendoor position was undone and analyzes the renewed activity around Quantum. He also explains how he is approaching options in the current market environment.

Episode 822: Martin Reveals He Lost Millions Shorting Quantum, How This Affects Opendoor Stock 21.09.2025

In this episode, Martin details how he lost millions while shorting Quantum and explains the sequence of events that led to the trade. He also discusses the broader market context and outlines how these developments may affect Opendoor’s stock going forward.

Episode 821: OPEN's CEO Won't Talk to Me, Atyr Gains are Gone, Quantum Nightmare is Back 20.09.2025

OPEN’s CEO is dodging calls, Atyr’s gains have vanished, and quantum investing is making noise again. Here’s what went down: – Ghosted by OPEN’s CEO – Atyr’s biotech rollercoaster – Quantum investing buzz

Episode 820: GALT Will Pay Us TWICE. Opendoor Stock is Value Short. When Atyr Got Too Obvious 18.09.2025

In this episode, Martin discusses why he believes GALT presents an opportunity that could pay off twice and analyzes his view on Opendoor as a value short. He also revisits Atyr, breaking down the factors that made the trade too obvious in hindsight.

Episode 819: Literally Gamestop 2.0. My Gains Are Gone. Opendoor Forecast 18.09.2025

In this episode, Martin talks through recent market moves he compares to a “Gamestop 2.0” scenario and reflects on how those shifts impacted his own gains. He also shares his latest forecast for Opendoor and what trends he’s watching in the stock.

Episode 818: $4 Million Evaporated. How 2 Portfolio Sizing, Kelly Criterion, HIMS vs FDA, Opendoor Martin Shkreli 17.09.2025

In this episode, Martin recounts how a $4 million position quickly evaporated and uses the experience to illustrate lessons in portfolio sizing and the Kelly Criterion. He also examines HIMS in the context of FDA considerations and provides updated thoughts on Opendoor.

Listen to the The Shkreli Pill podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.